130 related articles for article (PubMed ID: 28120035)
1. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.
Chen J; Solomides C; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2017 Feb; 79(2):369-380. PubMed ID: 28120035
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of mesothelioma cells to platinum-based chemotherapy by GSTπ knockdown.
Chen J; Solomides C; Simpkins H
Biochem Biophys Res Commun; 2014 Apr; 447(1):77-82. PubMed ID: 24690178
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
5. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
6. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
7. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
9. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic.
Liu S; Wang F; Yan L; Zhang L; Song Y; Xi S; Jia J; Sun G
Arch Toxicol; 2013 Jun; 87(6):981-9. PubMed ID: 23591579
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins.
Horibe S; Matsuda A; Tanahashi T; Inoue J; Kawauchi S; Mizuno S; Ueno M; Takahashi K; Maeda Y; Maegouchi T; Murakami Y; Yumoto R; Nagai J; Takano M
Life Sci; 2015 Mar; 124():31-40. PubMed ID: 25625243
[TBL] [Abstract][Full Text] [Related]
13. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
14. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
[TBL] [Abstract][Full Text] [Related]
15. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
16. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
Xue D; Zhou X; Qiu J
Biomed Pharmacother; 2020 Nov; 131():110676. PubMed ID: 32858502
[TBL] [Abstract][Full Text] [Related]
20. Lannea coromandelica (Houtt.) Merr. Induces Heme Oxygenase 1 (HO-1) Expression and Reduces Oxidative Stress via the p38/c-Jun N-Terminal Kinase-Nuclear Factor Erythroid 2-Related Factor 2 (p38/JNK-NRF2)-Mediated Antioxidant Pathway.
Alam MB; Kwon KR; Lee SH; Lee SH
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
